| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $811,566 ) |
| | 2023 | 2023 | IMMUNOGENICS LLC | 1600 DOVE ST | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | U44AI134590 | A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease | 002 | 5 | NIH | 8/28/2023 | $728,593 |
| | 2023 | 2022 | IMMUNOGENICS LLC | 1600 DOVE ST | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | U44AI134590 | A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease | 001 | 4 | NIH | 8/28/2023 | $0 |
| | 2023 | 2019 | IMMUNOGENX, INC. | 1600 DOVE ST | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | U44AI134590 | A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease | 000 | 1 | NIH | 4/14/2023 | $82,973 |
|
| Issue Date FY: 2022 ( Subtotal = $200,524 ) |
| | 2022 | 2022 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | U44AI134590 | A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease | 000 | 4 | NIH | 11/19/2021 | $200,524 |
|
| Issue Date FY: 2021 ( Subtotal = $1,932,190 ) |
| | 2021 | 2021 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | U44AI134590 | A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease | 000 | 3 | NIH | 11/16/2020 | $998,618 |
| | 2021 | 2021 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | R44DK121606 | A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease | 000 | 3 | NIH | 8/4/2021 | $933,572 |
| | 2021 | 2018 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | R33AT009637 | Latiglutenase as a Treatment for Celiac Disease | 000 | 2 | NIH | 9/4/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,234,934 ) |
| | 2020 | 2020 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | R44DK121606 | A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease | 000 | 2 | NIH | 9/6/2020 | $977,604 |
| | 2020 | 2020 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | R33AT009637 | Latiglutenase as a Treatment for Celiac Disease | 000 | 2 | NIH | 1/9/2020 | $259,102 |
| | 2020 | 2020 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | U44AI134590 | A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease | 002 | 2 | NIH | 3/5/2020 | $82,973 |
| | 2020 | 2020 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | R33AT009637 | Latiglutenase as a Treatment for Celiac Disease | 002 | 2 | NIH | 9/25/2020 | $0 |
| | 2020 | 2020 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | U44AI134590 | A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease | 000 | 2 | NIH | 2/28/2020 | $998,228 |
| | 2020 | 2019 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | U44AI134590 | A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease | 001 | 1 | NIH | 3/5/2020 | -$82,973 |
| | 2020 | 2018 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | R33AT009637 | Latiglutenase as a Treatment for Celiac Disease | 001 | 2 | NIH | 9/24/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $592,346 ) |
| | 2019 | 2019 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | U44AI134590 | A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease | 001 | 1 | NIH | 4/5/2019 | $0 |
| | 2019 | 2019 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | R44DK121606 | A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease | 000 | 1 | NIH | 8/6/2019 | $293,257 |
| | 2019 | 2019 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | U44AI134590 | A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease | 000 | 1 | NIH | 3/6/2019 | $299,089 |
| | 2019 | 2018 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | R33AT009637 | Latiglutenase as a Treatment for Celiac Disease | 000 | 2 | NIH | 1/17/2019 | $0 |
| | 2019 | 2018 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | R33AT009637 | Latiglutenase as a Treatment for Celiac Disease | 001 | 2 | NIH | 2/25/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $615,254 ) |
| | 2018 | 2018 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | R33AT009637 | Latiglutenase as a Treatment for Celiac Disease | 001 | 2 | NIH | 8/17/2018 | $615,254 |
| | 2018 | 2017 | IMMUNOGENICS LLC | 1600 DOVE ST STE 330 | NEWPORT BEACH | CA | 92660-1418 | ORANGE | USA | R33AT009637 | Latiglutenase as a Treatment for Celiac Disease | 000 | 1 | NIH | 8/16/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $592,996 ) |
| | 2017 | 2017 | IMMUNOGENICS, LLC | 501 ROCKFORD PL | CORONA DEL MAR | CA | 92625-2721 | ORANGE | USA | R33AT009637 | Latiglutenase as a Treatment for Celiac Disease | 000 | 1 | NIH | 9/6/2017 | $592,996 |
|
|
